XERIS PHARMACEUTICALS, INC., Issuer AND Trustee INDENTURE Dated as of June 30, 2020 Senior Debt SecuritiesIndenture • July 1st, 2020 • Xeris Pharmaceuticals Inc • Pharmaceutical preparations • New York
XERIS PHARMACEUTICALS, INC. and as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of June 30, 2020First Supplemental Indenture • July 1st, 2020 • Xeris Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Supplemental Indenture (as defined below) is being executed and delivered pursuant to Sections 2.01 and 2.02 of the Base Indenture (as defined below) to establish the terms, and provide for the issuance, of a new series of Securities (as defined in the Base Indenture) constituting the Company’s 5.00% Convertible Senior Notes due 2025 (the “Notes”).
